Chronic Disease
Our work in Chronic Disease
-
Association of Combination Statin and Antihypertensive Therapy With Reduced Alzheimer’s Disease and Related Dementia Risk
Drugs already being used to treat high blood pressure and cholesterol could reduce the risk of Alzheimer’s disease and dementia, according to a new Schaeffer Center study of nearly 700,000 Medicare beneficiaries.
Categorized in -
A Checklist to Help Prevent and Manage Pressure Injury
The Federal Appropriations legislative package referenced a simple protocol to prevent and manage pressure injury developed by Bill Padula.
-
Obesity, Second to Smoking as the Most Preventable Cause of US Deaths, Needs New Approaches
Nearly 40% of Americans are obese, and the numbers are climbing. The U.S. needs to get serious about solutions.
Categorized in -
Conflicts of Interest in Dialysis: A Barrier to Policy Reforms
What are the possible benefits and risks of nephrologist’s financial participation in dialysis facility joint venture (JV) arrangements and financial participation in End‐stage Kidney Disease Seamless Care Organizations (ESCOs)? Eugene Lin and co-authors examine possible mechanisms for disclosure and reporting of such arrangements as well as risk mitigation.
Categorized in -
Four Years Into MACRA: What Has Changed?
Changes to nephrology reimbursement present a unique opportunity to improve patient outcomes in a cost‐effective way. A multidisciplinary effort among policy makers, nephrology providers, and patient advocacy groups is critical to ensure these changes in care delivery safeguard and improve patient health.
Categorized in -
Policy Issues in Dialysis Care
The challenges that policymakers face when trying to encourage the delivery of high quality, cost‐efficient dialysis care to all patients who require dialysis are evident in the state of dialysis care today.
Categorized in -
Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations
Oncology care will benefit from a more rigorous approach to quality assessment. The success of oncology alternative payment models will require a robust set of quality measures that are relevant to patients, providers, and payers.
Categorized in -
Association Between Spending and Outcomes for Patients With Cancer
Overall cancer spending increased from $27 billion in 1990 to $137 billion in 2017 and is projected to increase further through 2020.
Categorized in -
Economic Value of Anti–Vascular Endothelial Growth Factor Treatment for Patients With Wet Age-Related Macular Degeneration in the United States
A new study suggests benefits to patient health and society top billions of dollars, or more, if adherence to wet age-related macular degeneration treatments could be improved.
Categorized in -
Treatments for the Leading Cause of Blindness in the US Generate $0.9 to $3 Billion for Society, According to New Economic Analysis
A new study suggests benefits to patient health and society top billions of dollars, or more, if adherence to wet age-related macular degeneration treatments could be improved.
Categorized in